Merck, Orna Therapeutics sign circular RNA collaboration deal valued at up to $3.65B

The companies will work together to discover, develop, and commercialize multiple oRNA programs, including vaccines and therapeutics, for infectious diseases and cancer.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Copyright © 1995-2016 Knight Sac Media. All rights reserved.Stock quotes are delayed at least 15 minutes - See Terms of Use.